Clinical efficacy observation of olmesartan combined with dapagliflozin in patients with chronic kidney disease stages 1-3

Hu Yan; Chen Zhonghui; Shu Changdong; Mei Jiben; He Jing; Chen Xueqin; Fan Hui

doi:10.11986/j.issn.1673-873X.2025.07.07

Abstract：Objective To investigate the clinical efficacy of olmesartan combined with dapagliflozin in patients with chronic kid-ney disease(CKD)stages 1-3,providing a reference for clinical treatment.Methods Using a random number table,102 CKD stage 1-3 patients admitted to Xuancheng People's Hospital from October 2022 to April 2024 were assigned to a control group and an experimental group,with 51 cases in each group.The control group received olmesartan medoxomil,while the experimental group received olmesartan combined with dapagliflozin.At 24 weeks of treatment,clinical efficacy was compared between the two groups.Levels of hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),nitric oxide(NO),serum creatinine(Scr),blood urea nitrogen(BUN),urine microalbumin(mAlb),and urine mi-cro albumin-to-creatinine ratio(UACR)were measured before treatment and at 24 weeks.Adverse events during treatment were also compared.Results The overall response rate in the experimental group was significantly higher than that in the control group(P＜0.05).No significant differences between the two groups in hs-CRP,IL-6,TNF-α,or NO were noted before treatment(P＞0.05).After treatment,hs-CRP,IL-6,TNF-α,and NO levels decreased in both groups compared to baseline,and the levels in the experimental group were lower than those in the control group,with statistically significant differences(P＜0.05).Like-wise,no significant differences between the groups in Scr,BUN,mAlb,and UACR were observed before treatment(P＞0.05);after treatment,these renal function indicators decreased significantly in both groups compared with baseline,and the experimental group showed significantly greater reductions than the control group(P＜0.05).No significant difference was found in the incidence of adverse reactions between the two groups during treatment(P＞0.05).Conclusion Olmesartan com-bined with dapagliflozin produces marked therapeutic efficacy in patients with CKD stages 1-3,effectively reducing inflamma-tory marker expression and protecting renal function,with good safety profiles,and thus merits promotion in clinical practice.